Pharmaron Stages $434 Million Hong Kong IPO, after Completing Shenzhen IPO in January
publication date: Nov 29, 2019
Pharmaron Beijing staged a $434 million Hong Kong IPO to expand its international CRO operations. In January, Pharmaron completed a $76 million IPO on the Shenzhen Exchange, and its stock price has quadrupled since its debut. The company said the dual registration will support its growth plans, including developing its global integrated service platform, R&D capability, M&A and strategic investments. Founded in 2004, with facilities in China, the US and UK staffed by over 7,000 employees, Pharmaron offers R&D services to partners in North America, Europe, Japan and China. More details....
Stock Symbols: (SHZ: 300759; HK: 3759)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.